Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNPAT | O15228 | 1/20 | 0.59 |
| ▸ | FNTA | P49354 | 3/20 | 0.53 |
| ▸ | FNTB | P49356 | 3/20 | 0.53 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.53 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.51 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.50 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.50 |
| ▸ | CTSC | P53634 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1711684 | 0.86 | C3AR1 (0.55) | GNPATFNTAFNTBPGGT1BERAP2 | |
| SCHEMBL6047680 | 0.86 | C3AR1 (0.55) | GNPATFNTAFNTBPGGT1BERAP2 | |
| SCHEMBL27757798 | 0.86 | C3AR1 (0.55) | GNPATFNTAFNTBPGGT1BERAP2 | |
| SCHEMBL17232586 | 0.86 | PAX8 (0.53) | GNPATFNTAFNTBPGGT1BFOLH1 | |
| SCHEMBL17254230 | 0.86 | PAX8 (0.53) | GNPATFNTAFNTBPGGT1BFOLH1 | |
| SCHEMBL9498688 | 0.85 | FOLH1 (0.67) | FOLH1 | |
| SCHEMBL28540087 | 0.85 | ERAP2 (0.65) | GNPATERAP2LNPEPCTSC | |
| SCHEMBL29372662 | 0.85 | ERAP2 (0.65) | GNPATERAP2LNPEPCTSC | |
| SCHEMBL12475970 | 0.85 | GNPAT (0.60) | GNPATERAP2LNPEPCTSCLTA4H | |
| SCHEMBL19173100 | 0.85 | GNPAT (0.60) | GNPATERAP2LNPEPCTSCLTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574249-A | Anti-CD 45 antibodies and conjugates thereof | VOR生物制药股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20260027224-A1 | ANTIBODY-DRUG CONJUGATES TARGETING CDH3 AND PREPARATION METHODS AND USES THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-29 | — | — | US | claimed |
| EP-4684807-A1 | LINKER AND USE THEREOF IN LIGAND DRUG CONJUGATE | Duality Biologics (Shanghai) Co., Ltd. (CN) | 2026-01-28 | — | — | EP | claimed |
| US-20260014270-A1 | ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATE AND METHOD FOR PREPARATION AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-01-15 | — | — | US | claimed |
| EP-4674840-A1 | CHEMICAL COUPLING LINKER AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2026-01-07 | — | — | EP | claimed |
| EP-4667495-A2 | BIOACTIVE MOLECULE CONJUGATE, PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-12-24 | — | — | EP | claimed |
| EP-4631952-A1 | GLUCOCORTICOID RECEPTOR AGONIST AND CONJUGATE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-10-15 | — | — | EP | claimed |
| EP-4603487-A1 | HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-20 | — | — | EP | claimed |
| EP-4603109-A1 | ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-20 | — | — | EP | claimed |
| WO-2024235130-A9 | POLYCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-26 | — | — | WO | claimed |
| CN-115975039-A | Recombinant fusion antibodies and antibody-drug conjugates and uses thereof | 中山大学 | 2023-04-18 | — | — | CN | claimed |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | ZYMEWORKS INC. | 2023-01-24 | — | — | US | claimed |
| WO-2022253035-A1 | ANTIBODY DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2022-12-08 | — | — | WO | claimed |
| CN-115279417-A | Bioactive substance conjugate and preparation method and application thereof | 苏州宜联生物医药有限公司 | 2022-11-01 | — | — | CN | claimed |
| EP-4051711-A2 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | Magenta Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | claimed |
| US-20220267441-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. | 2022-08-25 | — | — | US | claimed |
| WO-2022170971-A1 | BIOACTIVE SUBSTANCE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 苏州宜联生物医药有限公司 | 2022-08-18 | — | — | WO | claimed |
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. | 2022-06-09 | — | — | US | claimed |
| US-20220175951-A1 | Anti-CD45 Antibody Drug Conjugates and Uses Thereof | REGENERON PHARMACEUTICALS, INC. | 2022-06-09 | — | — | US | claimed |
| EP-3958910-A1 | ANTI-CD45 ANTIBODY DRUG CONJUGATES AND USES THEREOF | Magenta Therapeutics, Inc. (US) | 2022-03-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220175944-A1 | ANTI-CD117 ANTIBODY-DRUG CONJUGATES AND USES THEREOF | ITGB7, KIT, CD2 | GNPAT 2659/4885FNTA 4786/4885FNTB 3377/4885 |
| US-20260027224-A1 | ANTIBODY-DRUG CONJUGATES TARGETING CDH3 AND PREPARATION METHODS AND USES THEREOF | H1-3, H1-4, H1-2 | GNPAT 3685/4885FNTA 4752/4885FNTB 4002/4885 |
| US-20220175951-A1 | Anti-CD45 Antibody Drug Conjugates and Uses Thereof | CD47, ICOS, CD44 | GNPAT 3952/4885FNTA 4711/4885FNTB 4572/4885 |
| US-20220267441-A1 | ANTI-CD45 ANTIBODIES AND CONJUGATES THEREOF | CD2, CD44, CD47 | GNPAT 1467/4885FNTA 4101/4885FNTB 4123/4885 |
| US-11560422-B2 | Sulfonamide-containing linkage systems for drug conjugates | MPST, TPST2, SULT1A1 | GNPAT 243/4885FNTA 930/4885FNTB 1593/4885 |
| US-20260014270-A1 | ANTI-CEACAM5 ANTIBODY-DRUG CONJUGATE AND METHOD FOR PREPARATION AND USE THEREOF | TOP1, TNFSF10, CD2 | GNPAT 3730/4885FNTA 4450/4885FNTB 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.